Sanofi SA (SNY) Stock Analysis
Verdict: HOLD
Sanofi is a high-yield value play undergoing a structural pivot, where a 21% FCF yield offsets technical weakness and executive selling.
Investment score: 64/100
Analysis as of
Is Sanofi SA stock worth reviewing? The TradeMates thesis
Sanofi offers a rare combination of single-digit P/E and double-digit FCF yield, despite recent technical underperformance.
7-factor investment score
- Valuation: 85/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Sanofi SA opportunities and risks
What speaks for SNY
- Blockbuster Dupixent Expansion
What speaks against SNY
- Unsustainable Dividend Payout Ratio
Peers and competitors
- SAN.PA
- IPN.PA
- VIRP.PA
- MEDCL.PA
- VETO.PA
Frequently asked questions about Sanofi SA (SNY)
Is SNY stock a good investment?
The TradeMates model rates Sanofi SA as HOLD with an investment score of 64/100. Sanofi offers a rare combination of single-digit P/E and double-digit FCF yield, despite recent technical underperformance. This is algorithmic model output, not personal investment advice.
Is SNY stock a buy?
The TradeMates model verdict for SNY is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.